How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients

Kathryn L. Springer, Sunwen Chou, Shaobing Li, Roger H. Giller, Ralph Quinones, James E. Shira, Adriana Weinberg

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Infection with cytomegalovirus (CMV) remains a significant cause of morbidity and mortality among hematopoietic cell transplant (HCT) recipients. We describe two pediatric HCT recipients who developed persistent and severe drug-resistant CMV infections. CMV resistance to foscarnet and ganciclovir was detected after only 6 and 11 weeks of therapy, respectively. Viral pol mutations associated with drug resistance in these patients included T838A (a novel mutation) and D588N, which were shown by marker transfer to confer foscarnet and multidrug resistance, respectively. Each of these mutations significantly reduced in vitro replication of CMV, suggesting that they may decrease viral fitness. This finding was further supported by the disappearance of mutations upon withdrawal of antiviral pressure in one patient. Novel antivirals or combination therapy may be required for the treatment of drug-resistant CMV in HCT recipients and perhaps in other severely immunocompromised patients.

Original languageEnglish (US)
Pages (from-to)208-213
Number of pages6
JournalJournal of Clinical Microbiology
Volume43
Issue number1
DOIs
StatePublished - Jan 2005

Fingerprint

Viral Drug Resistance
Cytomegalovirus
Foscarnet
Transplants
Mutation
Cytomegalovirus Infections
Antiviral Agents
Ganciclovir
Immunocompromised Host
Multiple Drug Resistance
Drug Resistance
Pharmaceutical Preparations
Therapeutics
Pediatrics
Morbidity
Pressure
Mortality
Transplant Recipients

ASJC Scopus subject areas

  • Microbiology (medical)
  • Microbiology

Cite this

How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. / Springer, Kathryn L.; Chou, Sunwen; Li, Shaobing; Giller, Roger H.; Quinones, Ralph; Shira, James E.; Weinberg, Adriana.

In: Journal of Clinical Microbiology, Vol. 43, No. 1, 01.2005, p. 208-213.

Research output: Contribution to journalArticle

Springer, Kathryn L. ; Chou, Sunwen ; Li, Shaobing ; Giller, Roger H. ; Quinones, Ralph ; Shira, James E. ; Weinberg, Adriana. / How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. In: Journal of Clinical Microbiology. 2005 ; Vol. 43, No. 1. pp. 208-213.
@article{6708dbfaf7474334823015ddcf0b79b5,
title = "How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients",
abstract = "Infection with cytomegalovirus (CMV) remains a significant cause of morbidity and mortality among hematopoietic cell transplant (HCT) recipients. We describe two pediatric HCT recipients who developed persistent and severe drug-resistant CMV infections. CMV resistance to foscarnet and ganciclovir was detected after only 6 and 11 weeks of therapy, respectively. Viral pol mutations associated with drug resistance in these patients included T838A (a novel mutation) and D588N, which were shown by marker transfer to confer foscarnet and multidrug resistance, respectively. Each of these mutations significantly reduced in vitro replication of CMV, suggesting that they may decrease viral fitness. This finding was further supported by the disappearance of mutations upon withdrawal of antiviral pressure in one patient. Novel antivirals or combination therapy may be required for the treatment of drug-resistant CMV in HCT recipients and perhaps in other severely immunocompromised patients.",
author = "Springer, {Kathryn L.} and Sunwen Chou and Shaobing Li and Giller, {Roger H.} and Ralph Quinones and Shira, {James E.} and Adriana Weinberg",
year = "2005",
month = "1",
doi = "10.1128/JCM.43.1.208-213.2005",
language = "English (US)",
volume = "43",
pages = "208--213",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "1",

}

TY - JOUR

T1 - How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients

AU - Springer, Kathryn L.

AU - Chou, Sunwen

AU - Li, Shaobing

AU - Giller, Roger H.

AU - Quinones, Ralph

AU - Shira, James E.

AU - Weinberg, Adriana

PY - 2005/1

Y1 - 2005/1

N2 - Infection with cytomegalovirus (CMV) remains a significant cause of morbidity and mortality among hematopoietic cell transplant (HCT) recipients. We describe two pediatric HCT recipients who developed persistent and severe drug-resistant CMV infections. CMV resistance to foscarnet and ganciclovir was detected after only 6 and 11 weeks of therapy, respectively. Viral pol mutations associated with drug resistance in these patients included T838A (a novel mutation) and D588N, which were shown by marker transfer to confer foscarnet and multidrug resistance, respectively. Each of these mutations significantly reduced in vitro replication of CMV, suggesting that they may decrease viral fitness. This finding was further supported by the disappearance of mutations upon withdrawal of antiviral pressure in one patient. Novel antivirals or combination therapy may be required for the treatment of drug-resistant CMV in HCT recipients and perhaps in other severely immunocompromised patients.

AB - Infection with cytomegalovirus (CMV) remains a significant cause of morbidity and mortality among hematopoietic cell transplant (HCT) recipients. We describe two pediatric HCT recipients who developed persistent and severe drug-resistant CMV infections. CMV resistance to foscarnet and ganciclovir was detected after only 6 and 11 weeks of therapy, respectively. Viral pol mutations associated with drug resistance in these patients included T838A (a novel mutation) and D588N, which were shown by marker transfer to confer foscarnet and multidrug resistance, respectively. Each of these mutations significantly reduced in vitro replication of CMV, suggesting that they may decrease viral fitness. This finding was further supported by the disappearance of mutations upon withdrawal of antiviral pressure in one patient. Novel antivirals or combination therapy may be required for the treatment of drug-resistant CMV in HCT recipients and perhaps in other severely immunocompromised patients.

UR - http://www.scopus.com/inward/record.url?scp=11844275363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11844275363&partnerID=8YFLogxK

U2 - 10.1128/JCM.43.1.208-213.2005

DO - 10.1128/JCM.43.1.208-213.2005

M3 - Article

C2 - 15634973

AN - SCOPUS:11844275363

VL - 43

SP - 208

EP - 213

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 1

ER -